secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193805-25-001570
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q3 2025 net loss $25.6M; cash $35.1M; warns insufficient liquidity for 12 months
--------------------------------------------------------------------------------

- Net loss of $25.6M ($0.13/share) vs $24.4M ($0.24/share) in Q3 2024; nine-month loss $77.9M.
- Cash and equivalents $35.1M as of Sep 30, 2025; company states it lacks adequate liquidity to fund operations for 12 months without additional capital.
- R&D expenses $20.0M, down from $21.4M; G&A $6.0M, up from $4.4M.
- At ECTRIMS, presented CALLIPER data showing statistically significant 24-week confirmed disability improvement in progressive MS.
- Received USPTO Notice of Allowance for patent covering vidofludimus calcium dose strengths for PMS; top-line ENSURE data expected by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/0001193805-25-001570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-001570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer